11 Nov 2015 15:17
For immediate release | 11 November 2015 |
ABCAM PLC
("Abcam" or "the Company")
Application for admission to trading
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that pursuant to the agreement to acquire the entire issued share capital of AxioMx, Inc. announced earlier today, an application has been made to AIM for the admission to trading of 881,030 new ordinary shares of 0.2p each in the Company in connection with the Acquisition. The new ordinary shares will rank pari passu in all respects with the existing shares in issue (including the final dividend, the record date in respect of which is 13 November 2015). The new ordinary shares are subject to an orderly market agreement.
As a consequence of the issue of the new ordinary shares in connection with the Acquisition the Company's issued ordinary share capital comprises 202,208,530 ordinary shares of 0.2p each with voting rights. This figure may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Abcam under the FCA's Disclosure and Transparency Rules.
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Suzanne Smith, Company Secretary
| |
J.P.Morgan Cazenove - Nominated Adviser & Corporate Broker | + 44 (0) 20 7742 4000 |
James Mitford / Alex Bruce - Nominated Adviser | |
Notes to Editors
About Abcam
Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.
Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 130 countries. The Company was founded in 1998, and now employs over 820 people. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com